Table 1.
Outcome of rFVIIa treatment for 34 surgical procedures and 108 bleeding episodes in patients with Glanzmann’s thrombasthenia (data from Poon et al (2004))
| Category | N | Responsea (rate %)b |
Recurancec | Failured | Not evaluablea |
|---|---|---|---|---|---|
| Bleeding episodes (all) | 108 | 77(71/75) | 8 | 26 | 5 |
| GI | 17 | 9(53/53) | 1 | 8 | 0 |
| Epistaxes | 45 | 32(71/74) | 4 | 11 | 2 |
| Oropharynx | 29 | 23(79/79) | 2 | 6 | 0 |
| Miscellaneous sites | 17 | 13(76/93) | 1 | 1 | 3 |
| Surgical procedures (all) | 34 | 29(85/94) | 2 | 3 | |
| Major | 9 | 6(67/86) | 1 | 2 | |
| Minor – dental extraction | 9 | 9(100/100) | 0 | 0 | |
| Minor – others | 16 | 14(88/93) | 1 | 1 |
a
Response = cessation of bleeding within 48 h of initiation of rFVIIa treatment.
b
(intention-to-treat response rate in % / response rate of evaluable episodes in %).
c
Recurrence = bleeding that stopped in ≤48 h but with recurrence of bleeding in ≤48 h following cessation of initial bleeding.
d
Failure = Bleeding that stopped more than 48 h after the initiation of rFVIIa treatment and/or if another treatment (other than antifibrinolytic drugs) was needed.
e
Not evaluable = platelet transfusion(s) were given concurrently with rFVIIa.